Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production
- PMID: 18096327
- DOI: 10.1016/j.prp.2007.10.008
Lung granulomas from Mycobacterium tuberculosis/HIV-1 co-infected patients display decreased in situ TNF production
Abstract
Tuberculosis/HIV-1 co-infection is responsible for thousands of deaths each year, and previous studies have reported that co-infected individuals display major morphological alterations in tissue granulomas. The purpose of this study was to evaluate immunohistopathological characteristics in lung tissues from pulmonary TB/HIV-1-co-infected individuals. Following autopsy, tuberculosis-positive HIV-1-negative cases displayed granulomas with normal architecture, mainly composed of a mononuclear infiltrate with typical epithelioid, as well as giant cells, and exhibiting caseous necrosis. In contrast, lesions from the TB/HIV-1-co-infected group showed extensive necrosis, poorly formed granulomas, and a marked presence of polymorphonuclear cells. More importantly, TNF staining was greatly reduced in the TB/HIV-1-co-infected individuals. Our data suggest that HIV-1 infection alters the organization of pulmonary granulomas by modulating TNF and, possibly, cell trafficking, leading to an impaired anti-tuberculosis response.
Similar articles
-
Apoptosis is a major cause of so-called "caseous necrosis" in mycobacterial granulomas in HIV-infected patients.J Clin Pathol. 2008 Mar;61(3):366-72. doi: 10.1136/jcp.2007.050690. Epub 2007 Aug 30. J Clin Pathol. 2008. PMID: 17761737
-
Interferon-gamma-dependent mechanisms of mycobacteria-induced pulmonary immunopathology: the role of angiostasis and CXCR3-targeted chemokines for granuloma necrosis.J Pathol. 2007 Jul;212(3):295-305. doi: 10.1002/path.2185. J Pathol. 2007. PMID: 17534845
-
Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis.J Infect Dis. 2001 Jun 15;183(12):1805-9. doi: 10.1086/320725. Epub 2001 May 17. J Infect Dis. 2001. PMID: 11372035
-
Impact of tuberculosis on HIV-1 replication, diversity, and disease progression.AIDS Rev. 2002 Jul-Sep;4(3):165-76. AIDS Rev. 2002. PMID: 12416451 Review.
-
Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease.J Infect Dis. 2003 Oct 15;188(8):1146-55. doi: 10.1086/378676. Epub 2003 Sep 30. J Infect Dis. 2003. PMID: 14551885 Review.
Cited by
-
Proline-proline-glutamic acid (PPE) protein Rv1168c of Mycobacterium tuberculosis augments transcription from HIV-1 long terminal repeat promoter.J Biol Chem. 2012 May 11;287(20):16930-46. doi: 10.1074/jbc.M111.327825. Epub 2012 Mar 15. J Biol Chem. 2012. PMID: 22427668 Free PMC article.
-
Cell-mediated immune responses in tuberculosis.Annu Rev Immunol. 2009;27:393-422. doi: 10.1146/annurev.immunol.021908.132703. Annu Rev Immunol. 2009. PMID: 19302046 Free PMC article. Review.
-
Protein phosphatase, Mg2+/Mn2+-dependent 1A controls the innate antiviral and antibacterial response of macrophages during HIV-1 and Mycobacterium tuberculosis infection.Oncotarget. 2016 Mar 29;7(13):15394-409. doi: 10.18632/oncotarget.8190. Oncotarget. 2016. PMID: 27004401 Free PMC article.
-
Characteristics of patients co-infected with HIV at the time of inpatient tuberculosis treatment initiation in Yaoundé, Cameroon: a tertiary care hospital-based cross-sectional study.Arch Public Health. 2015 May 4;73(1):24. doi: 10.1186/s13690-015-0075-y. eCollection 2015. Arch Public Health. 2015. PMID: 25941570 Free PMC article.
-
An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management.Pharmaceuticals (Basel). 2023 Apr 12;16(4):581. doi: 10.3390/ph16040581. Pharmaceuticals (Basel). 2023. PMID: 37111338 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
